La Roche-Posay Lipikar Balm AP+M Moisturiser for Dry Skin 200ml

Lipikar Balm AP+M provides triple-action efficacy

Immediate Soothing, Anti-Scratching, Anti-Dry Skin Flare-Ups: A hydrating, Soothing balm for dry skin that is suitable for the whole family, including babies from 3 months. Suitable for use on eczema-prone skin. Also suitable for patients undergoing cancer treatment.

Efficacy:
Restoring triple-action balm to immediately soothe the skin and provide up to 48h hydration, so that itching sensations caused by dry skin are reduced for long-lasting comfort. AP+M formula restores the skin barrier function, reducing the frequency of dry skin flare-ups, and helps to rebalance the skin microbiome.

Active Ingredients:
Exclusive AP+M technology [Aqua Posae + Microresyl] in a formula that helps rebalance the microbiome and reduces the frequency of dry skin flare-ups. Combined with anti-irritation thermal spring water from La Roche-Posay, Niacinamide, 8% Glycerin and 20% Shea Butter this formula intensely soothes the skin and restores the skin barrier.

Microbiome Science:
La Roche-Posay is a pioneer in Microbiome science, leading research for nearly 10 years. The microbiome is the invisible ecosystem of bacteria on your skin, the balance of which helps ensure good skin health. This knowledge inspired the formula of LIPIKAR Balm AP+M.

Dermatologically Tested:
This gentle moisturising Baume has been through rigorous dermatological testing to ensure it is suitable for use on even the most sensitive skin, including babies from 3 months.

Minimalist Hypoallergenic Formula:
The minimalist, fragrance-free formula is designed for sensitive skin and its needs. Tested and re-tested for its efficacy and mildness on sensitive skin. The formula is also hypoallergenic.

9/10 UK DERMATOLOGISTS RECOMMEND LA ROCHE-POSAY FOR SENSITIVE SKIN* *Survey conducted on 267 dermatologists by La Roche-Posay in the UK, July 2019 La Roche-Posay is the No.1 dermatologist-recommended brand in the UK*. *Study of 73 Consultant Dermatologists Jan-April 2023.